p SEUDOMONAS AERUGINOSA, formerly called B. pyocyanea, is one of the group of gram-negative organisms that have caused an increased percentage of hospital-acquired infections in recent years. 1,1~ Because pseudomonas rarely produces primary infections in man, 6 it has been referred to as an "opportunist" organism, a term suggesting a micro-organism that is part of the normal flora of man but that occasionally produces progressive infections in a host with impaired defenses. Pseudomonas infections may be relatively indolent, producing only slow host reactions, and therefore may persist for long periods before being diagnosed and properly treated.
The characteristics noted above are particularly pertinent to pseudomonas infections of the central nervous system. Pseudomonas is the cause of about 5% of neonatal meningitis. 13,~4 In most instances pseudomonas meningitis has been superimposed on underlying disease, wound infection or eerebrospinal-fluid fistula; has extended from adjacent foci; or has been introduced by lumbar puncture, spinal anesthesia, or indwelling catheters draining cerebrospinal fluid. 2,3,~,~,12 In one large series, covering 10 years, pseudomonas was the causative organism in four out of 294 cases of bacterial meningitis (1.4%).5 An extensive review of reports of pseudomonas meningitis through 1955 is found in Forkner's monograph. 4 We are reporting 16 cases of pseudomonas infections of the central nervous system seen at the University of California Hospitals, and Fort Miley Veterans Administration Hospital, San Francisco, in the past 18 years. Two of the cases included in this series were described in detail previously. 7,s
Description of Cases
Terminal Sepsis. Pseudomonas meningitis occurred as a terminal infection in five patients. Three of these had extensive neoplastic disease, one had pancytopenia complicated by pseudomonas septicemia, and one had acute tubular necrosis complicated by pseudomonas septicemia. None had had adequate antibiotic therapy and all five patients died.
Brain Abscess. Two men, each about 65 years old, had brain abscesses due to pseudomonas. One died without treatment after a convulsive seizure, and an unruptured temporoparietal abscess was encountered at autopsy. Pulmonary emphysema was also present, and pseudomonas was cultured from the bronchi. The other patient had a multilocular temporal-lobe abscess in direct continuity with a cholesteatoma of the middle ear. Twelve days after craniotomy, signs of meningitis appeared and pseudomonas was cultured from the cerebrospinal fluid. Subsequent therapy with Polymyxin B (30 mg every 8 hours for 8 days) resulted in a cure.
Meningitis. There were nine cases of meningitis due to pseudomonas diagnosed during life (Table 1) . Four of these patients died, but one of these deaths was due to pulmonary embolism (Case 8) and CSF and blood cultures were negative at autopsy. One child (Case 3) died without having received adequate therapy now known to be necessary; the other child who died (Case 2) had had meningitis for about 3 weeks before specific intrathecal therapy was begun. The fourth patient who died (Case 6) had had a long debilitating course of illness before the meningitis occurred.
Another child with pseudomonas ventriculitis (Case 9) was cured of his infection by intraventricular Polymyxin B; however, extensive adhesions and webs within the ventricular system, noted prior to the start of 432 
Discussion
Infections of the central nervous system and cerebrospinal fluid due to pseudomonas are extremely serious and carry a high mortality. 2 This is partly due to the fact that these infections often appear during the terminal phase of an incurable illness. Pseudomonas meningitis may appear late in the course of a long debilitating illness, and a fatal outcome may result from this combination of conditions. Finally, the infection is often indolent and may not be recognized for a long period of time. However, our experiences described above, as well as those of others, suggest that meningitis or ventriculitis due to pseudomonas may be cured readily and without serious sequelae if proper therapy is begun soon after onset of the infection and reinfection is prevented.
Cure of pseudomonas meningitis with intrathecal Polymyxin B was first reported by Schoenbach, 11 and this has proved to be the best therapy available? Intrathecal dosage is 1 to 2 mg in infants, 3 to 5 mg in children over 2 years, and 5 to 10 mg in adults. These amounts administered daily for 3 days, then on alternate days for 2 to 3 weeks, have been successful in eradicating the infection. At this level, untoward drug effects have been minor, consisting only of occasional transient increase of signs of meningeal irritation. If pseudomonas infection is limited to the CNS, systemic Polymyxin B is unnecessary. If the CNS infection is suppressed but not eradicated, it may be reactivated by a ventriculoatrial shunt (Case 7), but after adequate treatment ventriculoatrial shunting may be done without reactivation of infection (Cases 7 and 9).
Summary
Our experience with 14 cases of pseudomonas meningitis and two cases of pseudomonas brain abscess has been described. Five of the cases of meningitis were terminal infections in the presence of other serious illnesses and adequate antimicrobial therapy was not used. Of the nine patients whose meningitis was diagnosed and treated, four died, but of these, one did not receive adequate intrathecal therapy and one died of pulmonary embolism after cure of the infection. Five adequately treated patients recovered from pseudomonas meningitis. One of the brain abscesses was cured while the other was an unsuspected autopsy finding.
Intrathecal or intraventricular Polymyxin B offers an effective and specific treatment for pseudomonas meningitis and if used in a proper dosage, the drug is tolerated fairly well. If the infection is confined to the cerebrospinal fluid space, systemic Polymyxin B therapy is not necessary.
